An observational study in Covid19, sponsored by University of Milan. Completed at 6 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-07-09.
Sponsored by University of Milan · Observational
Coronavirus Pathology is frequently associated with both diabetes mellitus and metabolic syndrome. In particular, results of observational studies and meta-analyzes configure diabetes as one of the main risk factors for the development of complications and unfavorable course of SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome), the syndromes caused respectively by SARS- VOC coronavirus and MERS-COV coronavirus. The available data confirm this association also in the clinical picture of the infection supported by SARS-COV 2 (COVID-19). In the epidemic outbreak that erupted at the beginning of 2020 in the Lombardy Region, about two thirds of the patients who died from COVID-19 were affected by diabetes mellitus. COVID-19 occurs in 70% of cases with an inflammatory pathology of the airways that can be fed by a cytokine storm and result in severe respiratory failure (10% cases) and death (5%). At the moment, the mainly involved pathophysiological molecular mechanisms are not clearly defined. It has been hypothesized that the transmembrane glycoprotein type II CD26, known for the enzyme activity Dipeptilpeptidase 4 exerted by its extracellular domain, may play a fundamental role in this process. In addition, it is considerably expressed at the parenchyma and lung interstitium level and carries out both systemic and paracrine enzymatic activity, modulating the activity of various proinflammatory cytokines, growth factors and vasoactive peptides at the level of the deep respiratory tract. The pulmonary parenchyma and the interstitium express significantly the Dipeptilpeptidase 4 protein, which in the Middle East Respiratory Syndrome favors the entry of the virus into the cells, thus allowing the virus to replicate within the cells and thus spread throughout the cell inside the organism. Dipeptilpeptidase 4 regulates the function of bioactive peptides and above all of cytokines, vasoactive peptides and chemokines present at the level of the mesothelium, of the deep respiratory tract (alveolar epithelium and alveolar bronchus), of endothelial and immune cells triggering the inflammatory storm. In line with this evidence, it has been hypothesized that acute respiratory disease from Coronavirus may depend on the massive localization of Dipeptilpeptidase 4 in lung tissue. Furthermore, the involvement of Dipeptilpeptidase 4 in other chronic respiratory diseases has been demonstrated. Starting from these observations we hypothesized that the selective blockade of Dipeptilpeptidase 4 can favorably modulate the pulmonary inflammatory response in the subject affected by COVID-19. Among the drugs that selectively block Dipeptilpeptidase 4, the one with greater affinity precisely for Dipeptilpeptidase 4 is Sitagliptin.
An observational, retrospective-case control, multi-center study is proposed to evaluate any effects of Sitagliptin on clinical, laboratory and instrumental parameters in the course of hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study. The evaluation will be performed by comparing the parameters of COVID-19 positive diabetic patients treated with Sitagliptin with those of a group of COVID-19 positive diabetic patients not treated with Sitagliptin. All diabetic subjects treated with Sitagliptin (100 mg / day, 50 mg / day or 25 mg / day) and all diabetic subjects not treated with Sitagliptin, eligible for inclusion / exclusion criteria, will be included in the analysis.
The clinical data of patients that will be collected anonymously during hospitalization will include: smoking habit, remote medical history aimed at assessing the presence of comorbidities (atrial fibrillation, heart failure, hypertension, arterial hypertension, chronic obstructive pulmonary disease, other lung disease, chronic renal failure, decay cognitive, Parkinson's disease, autoimmune diseases), pharmacological history (treatment introduced during hospitalization for COVID-19, respiratory failure or other complications; use of ACE-inhibitors, sartans, calcium channel blockers, diuretics, antiarrhythmics, beta blockers, anti-aggregants, anticoagulants, neuroleptics ). Anthropometric parameters including blood pressure measurement and BMI will also be collected.
For all patients, the following data will be collected at the baseline (first data available upon entry into the hospitalization regime) and upon discharge:
7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.
This study's enrollment of 338 is above the median of 261 across 3,136 observational studies indexed under COVID-19.
Browse COVID-19 studies →University of Milan is the lead sponsor of 177 studies on the registry; 27 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The anonymous data of diabetic patients hospitalized for COVID19 in the hospitals participating in the study will be collected
Exclusion Criteria:
The anonymous data relating to the clinical, laboratory and instrumental parameters of patients hospitalized for COVID-19 and suffering from type 2 diabetes treated with Sitagliptin will be extracted from the medical records currently in use in the centers participating in the study. The data will be anonymous and not attributable to individual subjects
Drug: Retrospective case-control analysis
The anonymous data relating to the clinical, laboratory and instrumental parameters of patients hospitalized for COVID-19 and suffering from type 2 diabetes not treated with Sitagliptin will be extracted from the medical records currently in use in the centers participating in the study. The data will be anonymous and not attributable to individual subjects
Drug: Retrospective case-control analysis
Evaluation of clinical, laboratory and instrumental parameters of diabetic patients during hospitalization for COVID-19. The data will be extracted anonymously from the computerized medical records commonly used in clinical practice by the centers involved in the study
Clinical parameter of acute lung disease
Clinical evaluation of physiological parameter "cough" associated with acute lung disease from the beginning of the study to the end of the study
Time frame: 1 month
Clinical parameter of acute lung disease
Variation of the clinical parameter "oxygen saturation by the use of a pulse oximeter" of acute lung disease from the beginning of the study to the end of the study
Time frame: 1 month
Clinical parameter of acute lung disease
Variation of the clinical parameter "body temperature" of acute lung disease from the beginning of the study to the end of the study
Time frame: 1 month
Clinical parameter of acute lung disease
Variation of the clinical parameter "PaO2/FiO2" of acute lung disease from the beginning of the study to the end of the study
Time frame: 1 month
Clinical parameter of acute lung disease
Variation of the clinical parameter "respiratory rate" of acute lung disease from the beginning of the study to the end of the study
Time frame: 1 month
Clinical parameter of acute lung disease
Variation of the clinical parameter "need for ventilator support" of acute lung disease from the beginning of the study to the end of the study
Time frame: 1 month
Clinical parameter of acute lung disease
Variation of the clinical parameter "duration in days of ventilator support, duration in days of oxygen therapy, duration in days of hospitalization, duration in days in the Intensive Care Unit, total length of stay in hospital" of acute lung disease from the beginning of the study to the end of the study
Time frame: 1 month
Death
Death of the patient during hospitalization due to COVID19
Time frame: 1 month
Biochemical parameter of acute lung disease
Variation of the biochemical parameter "reactive C protein" of acute lung disease from the beginning of the study to the end of the study
Time frame: 1 month
Biochemical parameter of acute lung disease
Variation of the biochemical parameter "blood count with formula" of acute lung disease from the beginning of the study to the end of the study
Time frame: 1 month
Biochemical parameter of acute lung disease
Variation of the biochemical parameter "erythrocyte sedimentation rate" of acute lung disease from the beginning of the study to the end of the study
Time frame: 1 month
Biochemical parameter of acute lung disease
Variation of the biochemical parameter "blood gas analysis" of acute lung disease from the beginning of the study to the end of the study
Time frame: 1 month
Biochemical parameter of acute lung disease
Variation of the biochemical parameter "LDH" of acute lung disease from the beginning of the study to the end of the study
Time frame: 1 month
Biochemical parameter of acute lung disease
Variation of the biochemical parameter "fasting blood glucose" of acute lung disease from the beginning of the study to the end of the study
Time frame: 1 month
Clinical parameter of acute lung disease
Variation of the clinical parameter "chest X ray" of acute lung disease from the beginning of the study to the end of the study
Time frame: 1 month
Plan to share: No
This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Milan